In this study, we show that MPN‐initiating NSC reside in a CD34+/CD38− fraction of neoplastic cells and that these MPN NSC exhibit several cytokine receptors and various clinically relevant target antigens and checkpoint molecules, including CD33 and PD‐L1. This evidence concerns the gene CD33 and myeloproliferative neoplasm.